TBPH insider transaction filings
Theravance Biopharma, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-08. Screen TBPH transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-08 | 4 | Samaha Eli — 10% owner | Sale (S): 1,400 @ $17.04 · Sale (S): 5,564 @ $17.17 | EDGAR |
| 2026-07-01 | 4 | Samaha Eli — 10% owner | Sale (S): 273,871 @ $17.23 · Sale (S): 25,027 @ $17.13 · Sale (S): 37,799 @ $17.00 | EDGAR |
| 2026-06-23 | 4 | Miller Aine — SVP, DEV & HEAD OF IRE OFFICE | Grant/award (A): 18,750 @ $0 | EDGAR |
| 2026-06-17 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Sale (S): 3,329 @ $16.39 · Sale (S): 3,328 @ $16.38 · Sale (S): 6,657 @ $16.39 | EDGAR |
| 2026-06-16 | 4 | GRAY SUSANNAH — Director | Grant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | O'Connor Donal — Director | Grant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Smaldone Alsup Laurie — Director | Grant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | MITCHELL DEAN J — Director | Grant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Miller Aine — SVP, DEV & HEAD OF IRE OFFICE | Tax withholding (F): 6,827 @ $16.55 | EDGAR |
| 2026-05-22 | 4 | Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARY | Tax withholding (F): 8,829 @ $16.55 | EDGAR |
| 2026-05-22 | 4 | Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICER | Tax withholding (F): 8,670 @ $16.55 | EDGAR |
| 2026-05-22 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Tax withholding (F): 5,678 @ $16.55 | EDGAR |
| 2026-05-22 | 4 | Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 20,038 @ $16.55 | EDGAR |
| 2026-04-03 | 4 | Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARY | Grant/award (A): 37,500 @ $0 | EDGAR |
| 2026-04-03 | 4 | Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICER | Grant/award (A): 37,500 @ $0 | EDGAR |
| 2026-04-03 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Grant/award (A): 18,750 @ $0 | EDGAR |
| 2026-04-03 | 4 | Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 75,000 @ $0 | EDGAR |
| 2026-03-18 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Sale (S): 7,767 @ $13.92 · Sale (S): 15,534 @ $14 · Sale (S): 7,766 @ $13.92 | EDGAR |
| 2026-02-24 | 4 | Miller Aine — SVP, DEV & HEAD OF IRE OFFICE | Tax withholding (F): 16,851 @ $19.66 | EDGAR |
| 2026-02-24 | 4 | Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARY | Tax withholding (F): 20,833 @ $19.66 | EDGAR |
| 2026-02-24 | 4 | Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICER | Tax withholding (F): 20,672 @ $19.66 | EDGAR |
| 2026-02-24 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Tax withholding (F): 13,929 @ $19.66 | EDGAR |
| 2026-02-24 | 4 | Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 74,975 @ $19.66 | EDGAR |
| 2025-12-05 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Sale (S): 7,767 @ $18.75 · Sale (S): 7,766 @ $18.75 · Sale (S): 15,534 @ $18.75 | EDGAR |
| 2025-12-01 | 4 | BROSHY ERAN — Director | Sale (S): 14,000 @ $20 · Sale (S): 15,501 @ $20 · Option exercise (M): 14,000 (derivative) @ $10.15 | EDGAR |
| 2025-11-24 | 4 | Miller Aine — SVP, DEV & HEAD OF IRE OFFICE | Tax withholding (F): 6,989 @ $17.90 | EDGAR |
| 2025-11-24 | 4 | Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARY | Tax withholding (F): 19,024 @ $17.90 | EDGAR |
| 2025-11-24 | 4 | Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICER | Tax withholding (F): 18,627 @ $17.90 | EDGAR |
| 2025-11-24 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Tax withholding (F): 9,060 @ $17.90 | EDGAR |
| 2025-11-21 | 4 | Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director | Gift (G): 9,900 @ $0 · Gift (G): 9,900 @ $0 · Tax withholding (F): 56,817 @ $17.90 | EDGAR |
| 2025-11-14 | 4/A | BROSHY ERAN — Director | Sale (S): 15,500 @ $18.50 · Sale (S): 15,500 @ $17 · Sale (S): 14,000 @ $18.50 · Option exercise (M): 14,000 (derivative) @ $10.15 | EDGAR |
| 2025-11-13 | 4 | BROSHY ERAN — Director | Sale (S): 29,500 @ $18.50 · Sale (S): 15,500 @ $17 · Sale (S): 14,000 @ $18.50 · Option exercise (M): 14,000 (derivative) @ $10.15 | EDGAR |
| 2025-08-22 | 4 | Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICER | Tax withholding (F): 9,368 @ $13.39 | EDGAR |
| 2025-08-22 | 4 | Miller Aine — SVP, DEV & HEAD OF IRE OFFICE | Tax withholding (F): 6,989 @ $13.39 | EDGAR |
| 2025-08-22 | 4 | Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARY | Tax withholding (F): 9,762 @ $13.39 | EDGAR |
| 2025-08-22 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Tax withholding (F): 9,096 @ $13.39 | EDGAR |
| 2025-08-22 | 4 | Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 15,394 @ $13.39 | EDGAR |
| 2025-07-16 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Sale (S): 682 @ $11.39 · Sale (S): 5,318 @ $11.39 · Sale (S): 4,000 @ $11.39 | EDGAR |
| 2025-06-25 | 4 | Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director | Gift (G): 20,000 @ $0 | EDGAR |
| 2025-06-17 | 4 | Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director | Gift (G): 9,600 @ $0 · Gift (G): 9,600 @ $0 | EDGAR |
| 2025-06-04 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Sale (S): 24,000 @ $11 | EDGAR |
| 2025-05-22 | 4 | Sawaf Aziz — SVP & CHIEF FINANCIAL OFFICER | Tax withholding (F): 9,348 @ $9.45 | EDGAR |
| 2025-05-22 | 4 | Grimaud Brett A. — SVP, GEN COUNSEL AND SECRETARY | Tax withholding (F): 9,743 @ $9.45 | EDGAR |
| 2025-05-22 | 4 | Farnum Rhonda — SVP, COMM & MEDICAL AFFAIRS | Tax withholding (F): 9,120 @ $9.45 | EDGAR |
| 2025-05-22 | 4 | Winningham Rick E — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 15,364 @ $9.45 | EDGAR |
| 2025-05-21 | 4 | Miller Aine — SVP, DEV & HEAD OF IRE OFFICE | Grant/award (A): 10,430 @ $0 · Tax withholding (F): 9,701 @ $9.45 | EDGAR |
| 2025-05-21 | 4 | O'Connor Donal — Director | Grant/award (A): 10,649 @ $0 · Grant/award (A): 24,258 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | GRAY SUSANNAH — Director | Grant/award (A): 10,649 @ $0 · Grant/award (A): 24,258 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Grant Jeremy T — Director | Grant/award (A): 10,649 @ $0 · Grant/award (A): 24,258 (derivative) @ $0 | EDGAR |
Recent 8-K events — Theravance Biopharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition ? 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TBPH returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →